Issued on behalf of Avant Technologies Inc.
VANCOUVER – USA News Group News Commentary – Artificial intelligence (AI) is still in the early stages of transforming healthcare—for both patients and providers. According to a recent Deloitte report, 71% of healthcare leaders expect profitability to improve this year, thanks in part to growing AI adoption across care systems. Globally, momentum is building: the World Health Organization (WHO) has launched a new AI collaboration center in partnership with the Digital Ethics Center at Delft University of Technology, while the World Economic Forum (WEF) is calling for greater investment in data, infrastructure, and equitable access. Meanwhile, the private sector is pushing innovation forward, with recent developments from companies like Avant Technologies, Inc. (OTCQB: AVAI), iCAD, Inc. (NASDAQ: ICAD), NVIDIA Corporation (NASDAQ: NVDA), Clover Health Investments, Corp. (NASDAQ: CLOV), and Alphabet Inc. (NASDAQ: GOOG, GOOGL).
The article continued: Analysts at McKinsey report that since 2023, a growing majority of healthcare leaders have embraced generative AI—85% say they’re either actively using or exploring the technology. Barclays projects the AI healthcare market will grow at an impressive compound annual rate (CAGR) of 30% through 2030, fueled by accelerating investment from pharmaceutical firms, hospitals, and insurers.
Avant Technologies and JV Partner, Ainnova, Accelerate Expansion Across Latin America Following Key Role at Healthcare Innovation Summit
Avant Technologies, Inc. (OTCQB: AVAI), an emerging leader in AI-driven healthcare innovation, continues to build momentum in the AI-driven healthcare sector through its joint venture with Ainnova Tech, a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI) and developers of the Vision AI platform. Today, the two companies announced that following Ainnova’s sponsorship and its CEO’s key role at the 2025 Healthcare Innovation Summit in Mexico City, both Avant and Ainnova, through their joint venture, Ai-nova Acquisition Corp. (AAC), are building on Ainnova’s strong presence in Mexico by expanding its footprint across Latin America.
Ainnova has initiated its first commercial pilots in both Chile and the Dominican Republic to work directly with prestigious hospitals that cover the full spectrum of care—from primary to highly specialized services. These pilot programs aim to demonstrate, (i) cost reduction in preventive diagnostics; (ii) increased efficiency in medical resource allocation and patient flow; (iii) enhanced institutional reputation driven by technological innovation; and (iv) improved profitability for participating healthcare centers through optimized patient referrals.
The pilot programs leverage Ainnova’s proprietary Vision AI platform to identify health risks in real time, which enable seamless referrals for specialty care or further diagnostic tests when a positive risk is detected. The broader vision for the joint venture involves deploying an automated, low-cost retinal imaging device integrated with its AI-driven platform to deliver comprehensive preventive risk screening. From just two retinal images, blood pressure and some lab test information, the system will assess risks for: cardiovascular disease (CVD), type 2 diabetes, liver fibrosis, and chronic kidney disease (CKD).
The message that Ainnova’s CEO, Vinicio Vargas, continues to convey to audiences around the world is that this accessible, fast, and scalable solution is designed to support early intervention and targeted treatment strategies, with the ambition of reaching millions of patients globally in the coming years.
Avant has partnered with Ainnova to form AAC so the two companies can advance and commercialize Ainnova’s technology portfolio worldwide. AAC holds the global licensing rights to the technology portfolio, including its Vision AI platform and is versatile proprietary retinal cameras and algorithms validated on more than 2.3 million clinical data points.
This also follows Ainnova's recent strategic alignment with Apollo Hospitals in Southeast Asia, where the Vision AI platform has been cleared for commercial deployment in Brazil, and clinical pilots are being prepared across the Americas. Avant and Ainnova have identified Brazil and the United States as key strategic markets. Ainnova is currently addressing regulatory pathways in Brazil with the support of its MDSAP certification to meet ANVISA requirements, paving the way for rapid market entry.
Ainnova is being guided by global CRO Fortrea ahead of the important pre-submission meeting with the FDA. The goal is to seek 510(k) clearance for Vision AI in detecting diabetic retinopathy, a gateway to broader use across multiple chronic disease categories.
At the same time, Ainnova is advancing its regulatory roadmap for the U. S. The objective is to begin clinical trials in the coming months to obtain FDA approval and commercialize its technology in the U.S.—initially targeting markets where reimbursement codes for diabetic retinopathy are already approved.
Between FDA progress, high-profile alliances, and a growing international presence, Avant Technologies continues to carve out a niche in the convergence of AI, diagnostics, and preventative care. Investors looking for small-cap exposure to the healthcare AI revolution may want to keep AVAI on the radar as these developments unfold.
CONTINUED… Read this and more news for Avant Technologies Inc. https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
iCAD, Inc. (NASDAQ: ICAD) recently appointed Mark Koeniguer as Chief Commercial Officer to lead its next phase of global growth in AI-powered breast health solutions. Koeniguer brings more than 30 years of MedTech and digital health experience, including a recent tenure as CEO of ScreenPoint Medical, where he drove a 400% increase in annual recurring revenue. At iCAD, he’ll oversee commercial sales, partnerships, and global expansion efforts.
“Mark’s deep expertise in the radiological health market and AI-powered solutions makes him an ideal leader for this new role,” said Dana Brown, President and CEO of iCAD. “As Chief Commercial Officer, he will be instrumental in positioning iCAD to better engage with global health providers seeking enterprise-wide solutions that elevate both clinical workflows and patient experiences. We are excited to welcome Mark to the team as we continue advancing our mission to transform breast cancer detection.”
NVIDIA Corporation’s (NASDAQ: NVDA) General Manager for healthcare, Kimberly Powell, recently emphasized that AI is already reshaping medical imaging workflows, calling it a natural entry point for automation in clinical settings. In a Q&A with Business Insider, Powell pointed to GE and IQVIA as prime examples of legacy healthcare players poised to scale with AI due to their deep data ecosystems.
“Some of these companies are 100 years old,” said Powell. “They're used to selling hardware. Their big transformation over the last decade of working with them has been how to not just read the sensor data so that another human can read it, but enhance the sensor data to see more things. De-noise it, or enhance, it or add AI on top of it.”
Powell believes the shift to AI-powered diagnostics could dramatically alter healthcare cost models by prioritizing early detection over treatment. While adoption may be slowed by outdated regulations and privacy concerns, she sees AI as an inevitable force in the evolution of care delivery.
Counterpart Health, a subsidiary of Clover Health Investments, Corp. (NASDAQ: CLOV), has partnered with Alphabet Inc. (NASDAQ: GOOG, GOOGL) subsidiary Google Cloud to bring Vertex AI Search into its clinician-facing Counterpart Assistant platform.
“Physicians are often under-resourced and lack access to cutting-edge technologies that can simplify care delivery,” said David Tsay, MD, Chief Medical Officer at Counterpart. “Our goal with Counterpart Assistant is to bring all the leading edge tools under one roof, layer them over a single source of normalized data, and give clinicians what they need to make informed decisions—without the burden of fragmented solutions.”
The move enables generative AI-powered search across fragmented health data systems, delivering instant insights from lab results, hospital discharges, medication adherence records, and more. The goal is to reduce time-consuming admin tasks and help physicians make faster, more informed decisions at the point of care. With this partnership, both companies are advancing the use of AI to streamline value-based healthcare delivery.
Source: https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
CONTACT:
USA NEWS GROUP
info@usanewsgroup.com
(604) 265-2873
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Related Stories
